Eric Cantor Tapped as PhRMA's New CEO — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PhRMA named former GOP House Majority Leader Eric Cantor as its next CEO, announced Tuesday in Washington.
- Cantor will confront mounting political pressure on drug prices and an increasingly populist mood from both political parties in his new role.
- The Trump administration is working to codify into law voluntary deals it struck with more than two dozen companies to lower U.S. pharmaceutical prices to peer-country levels.
- Democrats are also pursuing that most-favored-nation pricing approach and are weighing whether to add international prices to the criteria Medicare uses to negotiate drug prices.
Why it matters: PhRMA's recruitment of a former House GOP leader as its top lobbyist shows the industry gearing up for a drug-pricing fight that has drawn unusual bipartisan agreement — with the Trump administration pushing to enshrine voluntary deals struck with 20-plus companies, and Democrats weighing international reference pricing for Medicare negotiations.
Ask SkimNews
